SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
== Structure == Bacterial glutathione transferases of all classes are homodimeric enzymes (although heterodimeric isozymes of certain classes are also known). Monomers fold into a two-domain configuration to form the active enzyme structure. These globular proteins have an N-terminal domain that consists of a mixture of alpha-helices and beta strands, while the C-terminal domain is all-helical. The N-terminal domain contains the glutathione-binding site and is a highly conserved region among all GSTs. This domain has a similar composition to thioredoxins, which act as antioxidants by facilitating the reduction of other proteins. In comparison, the region that contains the greatest amount of variability between GST classes is contained in the alpha-2 helix on the C-terminal domain. The predominantly alpha-helical C-terminal domain is involved with the binding of hydrophobic substrates (such as hydrophobic portions of xenobiotics). The specificity of the alpha-2 helix stems from the assortment of amino acids in the domain that interacts with the glycine residue of glutathione.
==== MeSH E05.318.740 – statistics ==== MeSH E05.318.740.100 – actuarial analysis MeSH E05.318.740.150 – analysis of variance MeSH E05.318.740.150.500 – multivariate analysis MeSH E05.318.740.200 – area under curve MeSH E05.318.740.250 – cluster analysis MeSH E05.318.740.250.675 – small-area analysis MeSH E05.318.740.250.700 – space-time clustering MeSH E05.318.740.275 – confidence intervals MeSH E05.318.740.300 – data interpretation, statistical MeSH E05.318.740.350 – discriminant analysis MeSH E05.318.740.400 – factor analysis, statistical MeSH E05.318.740.475 – matched-pair analysis MeSH E05.318.740.500 – models, statistical MeSH E05.318.740.500.475 – likelihood functions MeSH E05.318.740.500.500 – linear models MeSH E05.318.740.500.525 – logistic models MeSH E05.318.740.500.600 – models, economic MeSH E05.318.740.500.600.500 – models, econometric MeSH E05.318.740.500.625 – nomograms MeSH E05.318.740.500.700 – proportional hazards models MeSH E05.318.740.525 – monte carlo method MeSH E05.318.740.600 – probability MeSH E05.318.740.600.200 – Bayes' theorem MeSH E05.318.740.600.400 – likelihood functions MeSH E05.318.740.600.500 – markov chains MeSH E05.318.740.600.600 – odds ratio MeSH E05.318.740.600.700 – proportional hazards models MeSH E05.318.740.600.800 – risk MeSH E05.318.740.600.800.450 – logistic models MeSH E05.318.740.600.800.715 – risk assessment MeSH E05.318.740.600.800.725 – risk factors MeSH E05.318.740.600.900 – uncertainty MeSH E05.318.740.750 – regression analysis MeSH E05.318.740.750.400 – least-squares analysis MeSH E05.318.740.750.425 – linear models MeSH E05.318.740.750.450 – logistic models MeSH E05.318.740.750.725 – proportional hazards models MeSH E05.318.740.872 – sensitivity and specificity MeSH E05.318.740.994 – statistical distributions MeSH E05.318.740.994.250 – binomial distribution MeSH E05.318.740.994.300 – chi-square distribution MeSH E05.318.740.994.500 – normal distribution MeSH E05.318.740.994.750 – poisson distribution MeSH E05.318.740.995 – statistics, nonparametric MeSH E05.318.740.996 – stochastic processes MeSH E05.318.740.996.500 – markov chains MeSH E05.318.740.998 – survival analysis MeSH E05.318.740.998.300 – disease-free survival
Also, ZEB1 is capable of conferring stem cell-like properties, thus strengthening the relationship between EMT and stemness. Thus, EMT may present increased danger to cancer patients, as EMT not only enables the carcinoma cells to enter the bloodstream, but also endows them with properties of stemness which increases tumorigenic and proliferative potential. However, recent studies have further shifted the primary effects of EMT away from invasion and metastasis, toward resistance to chemotherapeutic agents. Research on breast cancer and pancreatic cancer both demonstrated no difference in cells' metastatic potential upon acquisition of EMT. These are in agreement with another study showing that the EMT transcription factor TWIST actually requires intact adherens junctions in order to mediate local invasion in breast cancer. The effects of EMT and its relationship to invasion and metastasis may therefore be highly context specific. In urothelial carcinoma cell lines overexpression of HDAC5 inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition (EMT).
Sources: en.wikipedia.org
Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severely anemic individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues. Beta thalassemia occurs due to a mutation of the HBB gene leading to deficient production of the hemoglobin subunit beta-globin; the severity of the disease depends on the nature of the mutation, and whether or not the mutation is homozygous. The body's inability to construct beta-globin leads to reduced or zero production of adult hemoglobin thus causing anemia. The other component of hemoglobin, alpha-globin, accumulates in excess leading to ineffective production of red blood cells, increased hemolysis, and iron overload. Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing. As an inherited condition, beta thalassemia cannot be prevented although genetic counselling of potential parents prior to conception can propose the use of donor sperm or eggs. Patients may require repeated blood transfusions throughout life to maintain sufficient hemoglobin levels; this in turn may lead to severe problems associated with iron overload.
=== Telescopes === Solar Submillimeter Telescope, located in the "El Leoncito" Astronomical Complex Space Surveillance Telescope, a military telescope located at Exmouth, Western Australia. Spitzer Space Telescope, NASA infrared space observatory Swedish Solar Telescope
The Mystery of the Yellow Room at Project Gutenberg The Mystery of the Yellow Room at Standard Ebooks The Mystery of the Yellow Room public domain audiobook at LibriVox L'univers de Joseph Rouletabille, rouletabille.perso.cegetel.net (in French) The Mystery of the Yellow Room, audio version, litteratureaudio.com (in French) The Mystery of the Yellow Room at IMDb
Trump consistently supported Israel, though presented himself as the "candidate of peace". Trump also supported giving weapons to Israel, likely with "no strings attached", saying that it must "finish the problem". Trump was seen by some as more pro-Israel and less sympathetic to Palestine than Biden or Harris. Trump took a hardline stance against pro-Palestinian protests, telling donors he would "crush" them and deport non-citizen protestors to "set the movement back 25 or 30 years". At times, Trump was critical of Israel's conduct, saying Israel should "get it over with ... get back to peace and stop killing people". However, he pledged to end the war in Gaza through negotiation and bring peace to the Middle East. Trump called Biden's airstrikes on Yemen "crazy" and suggested negotiating with the Houthis.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.